

1 **Prevalence of coronary artery disease among COVID-19 patients: a systematic review and meta-**
2 **analysis**

3

4 Naushaba Akhtar¹, Bijaya Kumar Padhi², Muhammad Aaqib Shamim³, Nandhni Chiruganam
5 Gandhi⁴, Prakisini Satapathy⁵, Behdin Nowrouzi-Kia⁶, ,Ranjit Sah^{7,8,9}, Sarvesh Rustagi¹⁰ ,
6 Sanghamitra Pati^{1,*}, Vijay Kumar Chattu^{6,11,12,*}

7 ¹ Indian Council of Medical Research – Regional Medical Research Centre, Chandrasekharpur,
8 Bhubaneswar, 751023 India. Email: nakhtar118@gmail.com (NA),

9 drsanghamitra12@gmail.com (SP)

10 ² Department of Community Medicine and School of Public Health, Postgraduate Institute of
11 Medical Education and Research, Chandigarh, 160012 India. Email: bkpadhi@gmail.com
12 (BKP)

13 ³ Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. Email:
14 aaqibsh@gmail.com

15 ⁴ School of Dentistry, University of Dundee, Scotland, UK. Email: nandhni.g29@gmail.com

16 ⁵ Global Center for Evidence Synthesis, Chandigarh-160036, India. Email:
17 contact@gces.network

18 ^{6,13} ReSTORE Lab, Department of Occupational Science & Occupational Therapy, Temerty
19 Faculty of Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada

20 ⁷ Tribhuvan University Teaching Hospital, Kathmandu 46000, Nepal. Email:
21 ranjitsah@iom.edu.np

22 ⁸Department of Clinical Microbiology, DY Patil Medical College, Hospital and Research
23 Centre, DY Patil Vidyapeeth, Pune 411000, Maharashtra, India

24 ⁹Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y.
25 Patil Vidyapeeth, Pune 411018, Maharashtra, India

26 ¹⁰School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
27 Email: sarveshrustagi@uumail.in

28 ¹¹ Center for Transdisciplinary Research, Saveetha Dental College, Saveetha Institute of
29 Medical and Technological Sciences, Saveetha University, Chennai 602105, India

30 ¹² Department of Community Medicine, Faculty of Medicine, Datta Meghe Institute of
31 Medical Sciences, Wardha 442107, India

32 **Running/Short Title of Paper:** Coronary artery disease in COVID-19

33

34 **Corresponding Author(s)**

35 Dr Sanghamitra Pati: drsanghamitra12@gmail.com

36 Vijay Kumar Chattu: vijay.chattu@mail.utoronto.ca

37 **Prevalence of coronary artery disease among COVID-19 patients: a systematic review and meta-**
38 **analysis**

39 **Abstract**

40 **Background**

41 Throughout the surge of the COVID-19 pandemic high rate of chronic diseases have been
42 reported, including respiratory diseases and cardiovascular diseases. The prevalence of
43 coronary artery disease has remained high throughout the COVID-19 pandemic, which also
44 draws great concern towards it. This study seeks to provide a pooled estimate of the burden
45 of coronary artery disease in COVID-19.

46 **Objective**

47 To estimate the overall prevalence of coronary artery disease among COVID-19 patients.

48 **Data Sources**

49 In this systematic review and meta-analysis, an extensive literature search was conducted in
50 PubMed, Scopus, Embase, EBSCO, Web of Science, Cochrane, Proquest and preprint servers
51 (medRxiv, arXiv, bioRxiv, BioRN, ChiRxiv, ChiRN, and SSRN). References for eligible articles,
52 forward citation tracking, and expert opinion were used to identify other relevant articles.
53 All published articles until 13 April 2023 were assessed as per the PROSPERO registration
54 protocol (CRD42022367501).

55 **Study Selection, Data Extraction, and Synthesis**

56 Primary studies that reported coronary artery disease among COVID-19 patients were
57 included. The characteristics of the study and information on the number of cases of
58 coronary artery disease were extracted from the included studies. Individual study

59 estimates were pooled using the random intercept logistic regression model. The
60 heterogeneity between the selected studies was assessed using the I^2 statistic, tau, tau-
61 squared, Cochran's Q. Prediction interval was used to identify the range into which future
62 studies are expected to fall. Subgroup analysis based on geography (continent) was done to
63 reduce heterogeneity. Publication bias was analyzed using doi plot and LFK index. The risk of
64 bias in the studies was assessed as per the tools proposed by the National Institute of
65 Health.

66 **Main outcomes**

67 The primary outcome was the pooled prevalence of coronary artery disease among COVID-
68 19 patients within the examined population.

69 **Results**

70 510 records were initially retrieved from electronic databases in addition to other sources
71 like reference screening. 33 studies with 40,064 COVID-19 patients were included for
72 quantitative synthesis. The prevalence of coronary artery disease among COVID-19 patients
73 was 15.24% (95% CI: 11.41% - 20.06%). The prediction interval ranged from 2.49% to
74 55.90%. The studies were highly heterogeneous (tau-squared of 0.89), and subgroup
75 analysis significantly reduced it (test of moderators: $Q = 14.77$, $df=2$, $P=.002$). Europe
76 reported the highest prevalence [21.70% (14.80% - 30.65%)], and Asia has the least
77 prevalence [10.07% (6.55% - 15.19%)]. Meta-regression for sample size was not significant
78 ($P=.11$). A symmetric doi plot and an LFK index of 0.57 revealed no evidence of publication
79 bias or small-study effects.

80 **Conclusion**

81 The burden of coronary artery disease has been considerable, varying with geography. and
82 further research in this area is needed. Routine cardiac screening and assessment of COVID-
83 19 patients can help uncover undiagnosed cases, and better optimise the management of all
84 COVID-19 patients.

85

86 **Keywords:** coronary artery disease, COVID-19, ischaemic heart disease, myocardial
87 infarction, heart attack, Systematic Review, Meta-analysis

WITHDRAWN
see manuscript DOI for details

88 Introduction

89 The unprecedented challenge of the deadly COVID-19 has brought great concern for the
90 entire healthcare system. The high incidence due to high infectivity, and high prevalence
91 irrespective of the geographical constraints, has been a leading cause of this pandemic[1].
92 According to World Health Organization emergency diseases dashboard 2022, the cases have
93 reached 641,435,884 and 6621060 deaths globally till 06th December 2022. It hardly took
94 any time to be a major public health issue, and due to the lack of available treatment, the
95 transmission of disease also became easier.

96 The COVID-19 peak other co-morbidities and complications, even chronic conditions
97 resulting from COVID-19 infection has been clearly seen. There has been various studies
98 conducted which suggested that COVID-19 disease is a respiratory infection which can be a
99 leading cause of other co-morbidities or other co-morbid conditions that can affect the
100 occurrence of COVID-19 infection. As suggested in the first case report of COVID-19
101 infection will only affect older population with co-morbid conditions. Studies have revealed
102 the major and most prevalent co-morbidities as cardiovascular diseases, diabetes and
103 hypertension which has also shown positive association with SARS-CoV-2[2].

104 As the COVID-19 pandemic progressed with increased mortality and morbidity, their related
105 complications were also visible. The COVID-19 pandemic, along with respiratory failure,
106 gave rise to cardiological complications. Studies have revealed that the prevalence of
107 cardiovascular diseases was high during the COVID-19 surge[2], [3]. Researches conducted
108 during the ICU admissions also revealed the difficulty in recovery of patients with existing
109 cardiovascular complications like coronary artery disease, heart failure and stroke,
110 myocardial and atherosclerosis conditions mostly[4]. One of the study conducted in China

111 has also revealed that myocardial infarction or cardiovascular injury among patients
112 suffering from COVID-19 increases the chances of death[5]. A recent observational study
113 conducted at global levels has shown high coagulation and thrombotic events rates among
114 COVID-19 patients admitted in Intensive care units[6].The consequences of heart failure and
115 other inflammation-type responses, despite not having any prior history, have also been
116 observed in several types of research[7]. Several studies have also indicated that the
117 suffering of SARS CoV-2 actually doubled due to the presence of cardiovascular
118 complications, which made life more difficult and mortality more prevalent[8]. History of
119 heart failure or the existence of heart failure events leading to coronary artery disease may
120 complicate the situation and make management, diagnosis and prognosis even more
121 challenging [9], [10].

122 This study has highlighted complications that could result due to prevalence of coronary
123 artery diseases among COVID-19 patients. This article is a systematic study and meta-
124 analysis of the prevalence of coronary artery disease among patients with COVID-19. This
125 study tries to answer the question which raised concern of many epidemiologists and
126 physicians that whether any specific cardiovascular complications are more common in
127 COVID-19 disease condition.

128

129 **Methods**

130 ***Search strategy and selection criteria***

131 We searched seven databases: PubMed, Scopus, Web of Science, ProQuest, EMBASE, EBSCO
132 Host, and Cochrane. The pre-print servers (medRxiv, arXiv, bioRxiv, BioRN, ChiRxiv, ChiRN
133 and SSRN) are also included in our search strategy (Annexure 1). Furthermore, new eligible

134 studies were extracted by carefully searching for relevant references from included papers
135 and other suitable reviews. Using summary estimates, the primary outcome was the
136 prevalence of coronary artery disease among COVID-19 patients. The study has been
137 registered in the International Prospective Register of Systematic Reviews (PROSPERO) as
138 CRD42022367501.

139 The search keywords included 'coronary disease', 'COVID-19', and other synonymous words.
140 MeSH terms, and terms with an asterisk were used to identify related articles in the study
141 title (Annexure 1). Articles were saved in Mendeley Desktop V1.19.5 software to manage
142 citations, remove duplicates, and speed up the review process.

143 ***Data extraction and management***

144 Two authors (NA, NCG) individually reviewed each paper. The disagreement regarding the
145 selection of article, was resolved between two of the co-authors who conversed to build
146 consensus and agree. Any conflict between the two leading reviewers about the eligibility of
147 the publication, a third co-author (MAS) was consulted to assess the article and help choose
148 whether to include the study. The reviewers discovered five articles were relevant to the
149 main topic. Then from the eligible articles, the following information was gathered from
150 each source article: the author's name, the place where the study was conducted, the year
151 of publication, the study design, the number of COVID-19 cases, cases of coronary artery
152 disease, and other important details. A data extraction table has been prepared in a
153 Microsoft Excel spreadsheet for further analysis.

154 The articles searched were reported according to the PRISMA checklist (Preferred Reporting
155 Standard of Systematic Reviews and Meta-Analysis) to ensure scientific precision [Annexure

156 **2]**. In addition, the reviewers thoroughly read all of these publications before composing
157 their conclusions.

158 **Quality Assessment**

159 The studies were independently rated by two authors using the study quality assessment
160 tools as recommended by the National Institute of Health **[Annexure 3]**.

161 **Inclusion and Exclusion Criteria**

162 All articles published until 13th of April 2023 were considered for this study. The inclusion
163 and exclusion criteria have been given in **Annexure 4**.

164 **Data Analysis**

165 The prevalence of coronary artery disease among COVID-19 patients was calculated by
166 dividing the number of cases of coronary artery disease by the total number of study
167 participants. The proportions were transformed to the logarithmic scale. These were then
168 synthesised using a random intercept logistic regression model[11] . To describe the variance
169 amongst studies, the heterogeneity of the studies evaluated in the meta-analysis was
170 assessed using the I^2 test[12] , in addition to the prediction interval[13] , tau, tau-
171 squared[14] , and Cochran's Q [15]. Heterogeneity was classified as low, moderate, and
172 high, respectively, based on I^2 values of less than 25%, 25-50%, and more than 50%.
173 Therefore, the articles that were included in the meta-analysis were very heterogeneous. A
174 95% confidence interval using a random effect was used to evaluate the overall effect since
175 we anticipated considerable between-study heterogeneity and it was seen to be higher too.
176 $P < .05$ has been considered statistically significant. For the assessment of publication bias
177 and small-study effects, we used Doi plot and the accompanying LFK index since this is a
178 meta-analysis of proportions [13]. We performed a subgroup analysis based upon

179 geography (continent) of study population. 'meta' and 'metafor' packages in R version 4.2.1
180 were utilized for conducting the meta-analysis.

181 **Results**

182 The systematic search was initially performed on 30th November, 2022 and repeated on
183 13th April, 2022. It yielded 510 articles, among which 137 duplicates were detected and
184 removed. Two investigators (NA & NCG) independently reviewed the title/abstract
185 screening of the 373 articles, and 311 were removed. Additionally, several articles were
186 identified by checking the reference list of included studies, references in relevant reviews,
187 forward citation for eligible studies, a search in Google Scholar (not a primary database for
188 systematic reviews), and seeking the opinion of experts in the field. Full text screening of all
189 these selected records yielded 33 studies for inclusion in systematic review and meta-
190 analysis. [16]–[48] The PRISMA flow chart depicts the article selection and selection process
191 **[Figure 1]**.

192 15 of the 33 studies (45.45%) were conducted in Asia, 12 of the 33 (36.36%) in Europe, and 5
193 (15.15%) took place in North America. This study pooled data from several countries across
194 the globe [48]. The baseline characteristics of all the studies has been given in Table 1. It
195 mentions the authors, site of study, sample size, prevalence of coronary artery disease
196 among COVID-19 patients, and other key details. This Italian study [43] reported the highest
197 prevalence (68.92%) while the least prevalence (3.90%) was found in this study in Phillipines
198 [44].

199 ***Pooled prevalence***

200 Amongst the 33 studies reporting on the prevalence of coronary artery disease among
201 COVID-19 patients, we computed the pooled prevalence. It came to be 15.24% (95% CI:

202 11.41% - 20.06%). The prediction interval depicts the range into which future studies
203 exploring the same outcome are expected to report. This prediction interval ranged from
204 2.49% to 55.90% [Figure 2].

205 ***Heterogeneity estimation and exploration***

206 The individual study estimates showed considerable heterogeneity with an I^2 of 98.9% (95%
207 CI: 98.7% - 99.0 %), and a tau-squared of 0.89. The Cochran's Q is also significant with a
208 value by Wald's test of 4192.02 ($P < .001$). We used a random-effects model for the meta-
209 analysis due to this high heterogeneity. To reduce this heterogeneity, we performed
210 subgroup analysis and meta-regression.

211 Subgroup analyses based upon geographical criteria reduced heterogeneity. Dividing the
212 studies into continents resulted in three subgroups. There is a significant difference
213 between the three continents. This can be seen in the result of the test of moderators ($Q =$
214 14.77 , $df = 3$, $P = .002$). Europe reported the highest prevalence [21.70% (14.80% - 30.65%)],
215 and Asia has the least prevalence [10.07% (6.55% - 15.19%)]. Subgrouping also reduced the
216 heterogeneity in the individual subgroups. Details of the subgroup analysis is given in **Table**
217 **2**.

218 We conducted meta-regression based upon the sample size of individual studies. This was
219 not significant ($P = .11$). We constructed a bubble plot to visualize the same [Figure 3].

220 ***Assessment of publication bias and small-study effects***

221 We used a Doi plot and the accompanying LFK index to assess publication bias and small
222 study effects. The Doi plot showing individual study estimates against a folded quantile plot

223 can be seen in **Figure 4**. The LFK index is 0.57. This does not suggest publication bias for
224 estimation of prevalence of coronary artery disease among COVID-19 patients.

225 ***Risk of Bias Assessment***

226 The quality assessment of the findings of the included study is illustrated in the supplement
227 file (Table 2), with majority rated to have fair quality. The assessment of quality of the
228 included studies can be checked in the supplementary file (Annexure 2), with most studies
229 (32 out of 33) having fair quality, while one of the studies being poor in quality. Excluding
230 Barman et al., (2021), the only study with a poor quality slightly reduced the pooled
231 prevalence from 15.24% (95% CI: 11.41% - 20.06%) to 14.77% (95% CI: 10.84% - 19.81%)
232 [Annexure 5].

233

234 **Discussion**

235 This systematic review and meta-analysis results indicate that coronary artery disease is
236 significantly associated with COVID-19. This paper gives the pooled data on prevalence of
237 coronary artery disease complication in COVID-19 patient from the existing literature. The
238 pooled prevalence is 15.24% (95% CI: 11.41% - 20.06%), and varies by geography. It is higher
239 in Europe [21.70% (14.80% - 30.65%)], and lower in Asia [10.07% (6.55% - 15.19%)]. Some
240 studies conducted in the past also reveal SARS CoV-2 as the major precursor which invades
241 cardiac cells thereby leading to cardiovascular conditions like myocardial inflammation and
242 coronary artery disease[49].

243 Several studies show cardiovascular conditions such as coronary heart disease are
244 associated with increased risk for severe COVID-19 and mortality, hence investigating the

245 coronary heart disease prevalence can help stakeholders prioritize cardiovascular disease
246 healthcare resources[48]. This study gives detailed evidence from existing literature which
247 states the association between the two. The findings from this study can be utilized for
248 understanding the associating between coronary artery disease and COVID-19. This study
249 will help in clear understanding of clinical manifestations of COVID-19. This study identifies
250 evidences from different geographical locations which gives an insight into the disease
251 complications across the world[23]. The findings suggest a positive relationship with
252 increase in burden of coronary artery disease among COVID-19 patients which also provides
253 further scope for research in the similar area. There is need of more vigorous research in the
254 similar topic and future research can be conducted for multiple cardiovascular diseases
255 through sub-grouping of complications like myocardial infraction, atherosclerosis,
256 thrombosis, heart failure and stroke. These can be given importance and further
257 investigation on any of the above can also be conducted. The findings from this study
258 provides a brief overview of the burden of coronary artery disease among COVID-19
259 patients. This would enable the healthcare providers, researchers and policy makers to
260 more accurately assess the issue, identify the threats in this area and develop strategies to
261 accomplish them.

262 ***Strengths and limitations***

263 This systematic review and meta-analysis included studies across multiple databases of
264 published and unpublished literature to quantify and study the prevalence of coronary
265 artery disease among COVID-19 patients, which is the first of its kind, globally. The risk of
266 bias in the studies have been assessed using standard tools. However, the present analysis
267 was not devoid of limitations. There was significantly high heterogeneity among the

268 included studies, a poor-quality study was included in the analysis, and a lack of detailed
269 description of the disease in many studies. The substantial heterogeneity observed in the
270 study is hypothesised due to the global nature of the data in the review with varied patient
271 characteristics in terms of geographic location, health facilities, and other co-morbidities in
272 the various studies.

273 **Conclusions**

274 This systematic review and meta-analysis examined 40,064 individuals from 33 studies and
275 found 5333 patients with coronary artery disease in COVID-19 patients. The overall pooled
276 prevalence of coronary artery disease in COVID-19 is 15.24%. Given the high prevalence,
277 there is a necessity to assess cardiac health of COVID-19 patient admitted in the hospital
278 with diagnostic methods such as ECG, 2D echo. This study highlights the need for further
279 research in coronary artery disease and other cardiac diseases in COVID-19 patients
280 alongwith research on evaluating cardiac biomarkers, ECG changes and other screening
281 procedures.

282 **Contributors**

283 Dr Bijay kumar padhi & NA conceptualized the study and designed the protocol. NA did the
284 PROSPERO registration. NA & NCG did the literature review, collected data and the quality
285 assessment of the studies NA, MAS & NCG for the data. Dr Bijay kumar padhi interpreted
286 the data. NA prepared the initial draft of the manuscript. Dr Bijay kumar padhi have
287 reviewed, edited, and provided critical comments. Finally, NA & MAS edited the final draft
288 and upadated the studies with the team's amendment of critical revisions and essential
289 suggestions. All authors had full access to all the data in the study and had the final
290 responsibility for the decision to submit for publication.

291

292 **Declaration of Interest**

293 None of the authors has declared any competing interests.

294

295 **Funding**

296 Indian Council of Medical Research – Senior Research Fellow [CTU/Fellowship/03/2022-ECD-

297 II - 5th May 2022]

298

299 **Data Sharing**

300 All data generated or analyzed during this study are included in this published article [and its

301 supplementary information files].

302

303 **Table Captions**

304 **Table 1:** Brief summary of the studies featured in the meta-analysis (N=33)[51]–[55]

305 **Table 2:** Subgroup analysis for pooled prevalence of coronary artery disease among COVID-

306 19 patients – based on continent

307

308 **Figure Captions**

309 **Figure 1.** PRISMA flow chart for included studies in systematic review and meta-analysis of

310 prevalence of coronary artery disease among COVID-19 patients

311 **Figure 2.** Pooled prevalence forest plot of coronary artery disease among COVID-19
312 patients.

313 **Figure 3.** Bubble plot based on the prevalence of coronary artery disease among COVID-19
314 patients.

315 **Figure 4.** Doi plot and LFK index to assess publication bias and small-study effects for
316 prevalence of coronary artery disease among COVID-19 patients.

317

318 **Supplementary material**

319 **Annexure 1:** Adjusted search terms as per searched electronic databases.

320 **Annexure 2:** PRISMA checklist for reporting of the systematic review and meta-analysis

321 **Annexure 3:** Quality assessment of included studies.

322 **Annexure 4:** Inclusion and Exclusion Criteria

323 **Annexure 5:** Sensitivity analysis excluding a poor quality study.

324

325 References

- 326 [1] M. Bansal, "Cardiovascular disease and COVID-19," *Diabetes Metab. Syndr. Clin. Res. Rev.*, vol.
327 14, no. 3, pp. 247–250, 2020, doi: 10.1016/j.dsx.2020.03.013.
- 328 [2] R. Ningthoujam and D. Khomdrum, "WHO statement – 'Older people are at highest risk from
329 COVID-19': Should the hypothesis be corroborated or rejected?," *Med. Hypotheses*, vol. 144,
330 2020, doi: 10.1016/j.mehy.2020.109896.
- 331 [3] S. Harikrishnan *et al.*, "Cardiological society of India position statement on COVID-19 and heart
332 failure," *Indian Heart J.*, vol. 72, no. 2, pp. 75–81, 2020, doi: 10.1016/j.ihj.2020.04.012.
- 333 [4] B. Kumar, A. Kodliwadmam, A. Upadhyay, A. Singh, and N. N., "Apparently normal epicardial
334 coronaries in a patient with inferior wall myocardial infraction on the background of mild
335 coronavirus disease-2019: take a second look!," *Monaldi Arch Chest Dis*, vol. 91, no. 3, 2021,
336 doi: 10.4081/monaldi.2021.1668.
- 337 [5] M. J. Ahlers *et al.*, "Characteristics and outcomes of patients presenting with acute myocardial
338 infarction and cardiogenic shock during COVID-19," *Catheter Cardiovasc Interv*, vol. 100, no. 4,
339 pp. 568–574, Oct. 2022, doi: 10.1002/ccd.30390.
- 340 [6] R. Yalamanchi *et al.*, "Cardiac intensive care unit admissions during covid-19 pandemic—single
341 center experience," *Indian J. Crit. Care Med.*, vol. 24, no. 11, pp. 1103–1105, 2020, doi:
342 10.5005/jp-journals-10071-23660.
- 343 [7] Z. Wang *et al.*, "Red blood cell distribution width: A severity indicator in patients with
344 COVID-19," *Journal of Medical Virology*, vol. 94, no. 5, pp. 2133–2138, May 2022, doi:
345 10.1002/jmv.27602.
- 346 [8] T. Abe *et al.*, "Cardiovascular complications in COVID-19 patients with or without diabetes
347 mellitus," *Endocrinol. Diabetes Metab.*, vol. 4, no. 2, 2021, doi: 10.1002/edm2.218.
- 348 [9] R. Choudhary, A. Kaushik, and J. B. Sharma, "COVID-19 pandemic and stent thrombosis in a
349 post percutaneous coronary intervention patient—a case report highlighting the selection of
350 P2Y12 inhibitor," *Cardiovasc. Diagn. Ther.*, vol. 10, no. 4, pp. 898–901, 2020, doi:
351 10.21037/cdt-20-485.
- 352 [10] N. Garg, B. McClafferty, D. Ramgobin, R. Golamari, R. Jain, and R. Jain, "Cardiology and COVID-
353 19: Do we have sufficient information?," *Future Cardiol.*, vol. 17, no. 4, pp. 705–711, 2021, doi:
354 10.2217/fca-2020-0126.
- 355 [11] T. Stijnen, T. H. Hamza, and P. Ozdemir, "Random effects meta-analysis of event outcome in
356 the framework of the generalized linear mixed model with applications in sparse data.,"
357 *Statistics in medicine*, vol. 29, no. 29, pp. 3046–67, Dec. 2010, doi: 10.1002/sim.4040.
- 358 [12] J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in a meta-analysis.," *Statistics
359 in medicine*, vol. 21, no. 11, pp. 1539–58, Jun. 2002, doi: 10.1002/sim.1186.
- 360 [13] M. A. Shamim, P. Dwivedi, and B. K. Padhi, "Beyond the Funnel Plot: The Advantages of Doi
361 Plots and Prediction Intervals in Meta-Analyses," *Asian Journal of Psychiatry*, pp. 103550–
362 103550, Mar. 2023, doi: 10.1016/j.ajp.2023.103550.
- 363 [14] A. A. Veroniki *et al.*, "Methods to estimate the between-study variance and its uncertainty in
364 meta-analysis.," *Research synthesis methods*, vol. 7, no. 1, pp. 55–79, Mar. 2016, doi:
365 10.1002/jrsm.1164.
- 366 [15] W. G. Cochran, "The Combination of Estimates from Different Experiments," *Biometrics*, vol.
367 10, no. 1, pp. 101–101, Mar. 1954, doi: 10.2307/3001666.
- 368 [16] Y. Xie *et al.*, "Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of
369 Coronavirus Disease 2019 (COVID-19)," *Circ J*, vol. 84, no. 8, pp. 1277–1283, Jul. 2020, doi:
370 10.1253/circj.CJ-20-0348.
- 371 [17] N. Aladağ and R. D. Atabey, "The role of concomitant cardiovascular diseases and cardiac
372 biomarkers for predicting mortality in critical COVID-19 patients," *Acta Cardiologica*, vol. 76,
373 no. 2, pp. 132–139, Mar. 2021, doi: 10.1080/00015385.2020.1810914.

- 374 [18] H. A. Barman *et al.*, “Prognostic significance of cardiac injury in COVID-19 patients with and
375 without coronary artery disease,” *Coronary Artery Disease*, vol. 32, no. 5, p. 359, Aug. 2021,
376 doi: 10.1097/MCA.0000000000000914.
- 377 [19] E. Bruce *et al.*, “Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
378 Important Outcomes in Hospitalised Patients with COVID-19,” *JCM*, vol. 9, no. 8, p. 2586, Aug.
379 2020, doi: 10.3390/jcm9082586.
- 380 [20] Y. Cen *et al.*, “Risk factors for disease progression in patients with mild to moderate
381 coronavirus disease 2019—a multi-centre observational study,” *Clinical Microbiology and*
382 *Infection*, vol. 26, no. 9, pp. 1242–1247, Sep. 2020, doi: 10.1016/j.cmi.2020.05.041.
- 383 [21] N. Gupta *et al.*, “Evaluation of the clinical profile, laboratory parameters and outcome of two
384 hundred COVID-19 patients from a tertiary centre in India,” *Monaldi Archives for Chest Disease*,
385 vol. 90, no. 4, Art. no. 4, Nov. 2020, doi: 10.4081/monaldi.2020.1507.
- 386 [22] J. Hewitt *et al.*, “The effect of frailty on survival in patients with COVID-19 (COPE): a
387 multicentre, European, observational cohort study,” *The Lancet Public Health*, vol. 5, no. 8, pp.
388 e444–e451, Aug. 2020, doi: 10.1016/S2468-2667(20)30146-8.
- 389 [23] G. Iaccarino *et al.*, “Age and Multimorbidity Predict Death Among COVID-19 Patients,”
390 *Hypertension*, vol. 76, no. 2, pp. 366–372, Aug. 2020, doi:
391 10.1161/HYPERTENSIONAHA.120.15324.
- 392 [24] F. Lagi *et al.*, “Early experience of an infectious and tropical diseases unit during the
393 coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020,”
394 *Eurosurveillance*, vol. 25, no. 17, p. 2000556, Apr. 2020, doi: 10.2807/1560-
395 7917.ES.2020.25.17.2000556.
- 396 [25] M. E. Lendorf *et al.*, “Characteristics and early outcomes of patients hospitalised for COVID-19
397 in North Zealand, Denmark,” *Dan Med J*, vol. 67, no. 9, p. A06200428, Aug. 2020.
- 398 [26] J. Li, G. Xu, H. Yu, X. Peng, Y. Luo, and C. Cao, “Clinical Characteristics and Outcomes of 74
399 Patients With Severe or Critical COVID-19,” *The American Journal of the Medical Sciences*, vol.
400 360, no. 3, pp. 229–235, Sep. 2020, doi: 10.1016/j.amjms.2020.05.040.
- 401 [27] Y. Liao *et al.*, “Clinical characteristics and prognostic factors of COVID-19 patients progression
402 to severe: a retrospective, observational study,” *Aging*, vol. 12, no. 19, pp. 18853–18865, Oct.
403 2020, doi: 10.18632/aging.103931.
- 404 [28] M. K. Turagam *et al.*, “Malignant Arrhythmias in Patients With COVID-19,” *Circulation:*
405 *Arrhythmia and Electrophysiology*, vol. 13, no. 11, p. e008920, Nov. 2020, doi:
406 10.1161/CIRCEP.120.008920.
- 407 [29] M. G. Argenziano *et al.*, “Characterization and clinical course of 1000 patients with coronavirus
408 disease 2019 in New York: retrospective case series,” *BMJ*, vol. 369, p. m1996, May 2020, doi:
409 10.1136/bmj.m1996.
- 410 [30] R. Chen *et al.*, “Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus
411 Disease 2019 From a Nationwide Analysis in China,” *CHEST*, vol. 158, no. 1, pp. 97–105, Jul.
412 2020, doi: 10.1016/j.chest.2020.04.010.
- 413 [31] Q. Deng *et al.*, “Suspected myocardial injury in patients with COVID-19: Evidence from front-
414 line clinical observation in Wuhan, China,” *International Journal of Cardiology*, vol. 311, pp.
415 116–121, Jul. 2020, doi: 10.1016/j.ijcard.2020.03.087.
- 416 [32] H. Xingwei *et al.*, “Impact of complicated myocardial injury on the clinical outcome of severe or
417 critically ill COVID-19 patients,” *Chinese Journal of Cardiology*, vol. 48, no. 06, Art. no. 06, Jun.
418 2020, doi: 10.3760/cma.j.cn112148-20200228-00137.
- 419 [33] C. Lodigiani *et al.*, “Venous and arterial thromboembolic complications in COVID-19 patients
420 admitted to an academic hospital in Milan, Italy,” *Thrombosis Research*, vol. 191, pp. 9–14, Jul.
421 2020, doi: 10.1016/j.thromres.2020.04.024.
- 422 [34] S. Shi *et al.*, “Characteristics and clinical significance of myocardial injury in patients with
423 severe coronavirus disease 2019,” *European Heart Journal*, vol. 41, no. 22, pp. 2070–2079, Jun.
424 2020, doi: 10.1093/eurheartj/ehaa408.

- 425 [35] S. Tai *et al.*, "Association between Cardiovascular Burden and Requirement of Intensive Care
426 among Patients with Mild COVID-19," *Cardiovascular Therapeutics*, vol. 2020, p. e9059562,
427 Aug. 2020, doi: 10.1155/2020/9059562.
- 428 [36] P. G. Rossi *et al.*, "Characteristics and outcomes of a cohort of COVID-19 patients in the
429 Province of Reggio Emilia, Italy," *PLOS ONE*, vol. 15, no. 8, p. e0238281, Aug. 2020, doi:
430 10.1371/journal.pone.0238281.
- 431 [37] S. F. Lax *et al.*, "Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome," *Ann Intern
432 Med*, vol. 173, no. 5, pp. 350–361, Sep. 2020, doi: 10.7326/M20-2566.
- 433 [38] R. M. Inciardi *et al.*, "Characteristics and outcomes of patients hospitalized for COVID-19 and
434 cardiac disease in Northern Italy," *European Heart Journal*, vol. 41, no. 19, pp. 1821–1829, May
435 2020, doi: 10.1093/eurheartj/ehaa388.
- 436 [39] J. Zhang *et al.*, "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan,
437 China," *Allergy*, vol. 75, no. 7, pp. 1730–1741, 2020, doi: 10.1111/all.14238.
- 438 [40] S. Richardson *et al.*, "Presenting Characteristics, Comorbidities, and Outcomes Among 5700
439 Patients Hospitalized With COVID-19 in the New York City Area," *JAMA*, vol. 323, no. 20, pp.
440 2052–2059, May 2020, doi: 10.1001/jama.2020.6775.
- 441 [41] L. Zhang *et al.*, "Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan,
442 China," *Circulation*, vol. 142, no. 2, pp. 114–128, Jul. 2020, doi:
443 10.1161/CIRCULATIONAHA.120.046702.
- 444 [42] Y. Du *et al.*, "Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective
445 Observational Study," *Am J Respir Crit Care Med*, vol. 201, no. 11, pp. 1372–1379, Jun. 2020,
446 doi: 10.1164/rccm.202003-0543OC.
- 447 [43] A. Scoccia *et al.*, "Impact of clinical and subclinical coronary artery disease as assessed by
448 coronary artery calcium in COVID-19," *Atherosclerosis*, vol. 328, pp. 136–143, Jul. 2021, doi:
449 10.1016/j.atherosclerosis.2021.03.041.
- 450 [44] R. D. G. Jamora, M. B. Prado, V. M. M. Anlacan, M. C. C. Sy, and A. I. Espiritu, "Incidence and
451 risk factors for stroke in patients with COVID-19 in the Philippines: An analysis of 10,881
452 cases," *Journal of Stroke and Cerebrovascular Diseases*, vol. 31, no. 11, p. 106776, Nov. 2022,
453 doi: 10.1016/j.jstrokecerebrovasdis.2022.106776.
- 454 [45] R. Bali and R. K. Calton, "Cardiovascular complications in COVID-19: A comparative study of
455 clinical characteristics and their effect on the outcome of first wave and second wave," *Indian
456 Heart J*, vol. 73, pp. S66–S67, Dec. 2021, doi: 10.1016/j.ihj.2021.11.129.
- 457 [46] C. Meloche *et al.*, "CARDIOVASCULAR DISEASE AND OUTCOMES IN CRITICALLY ILL PATIENTS
458 WITH COVID-19: A STOP-COVID ANCILLARY," *J Am Coll Cardiol*, vol. 77, no. 18, p. 3127, May
459 2021, doi: 10.1016/S0735-1097(21)04482-X.
- 460 [47] L. Slipczuk *et al.*, "Coronary artery calcification and epicardial adipose tissue as independent
461 predictors of mortality in COVID-19," *Int J Cardiovasc Imaging*, vol. 37, no. 10, pp. 3093–3100,
462 Oct. 2021, doi: 10.1007/s10554-021-02276-2.
- 463 [48] D. Prabhakaran *et al.*, "Cardiovascular Risk Factors and Clinical Outcomes among Patients
464 Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study," vol.
465 17, no. 1, Art. no. 1, Jun. 2022, doi: 10.5334/gh.1128.
- 466 [49] A. Docea *et al.*, "A new threat from an old enemy: Reemergence of coronavirus (Review)," *Int
467 J Mol Med*, Mar. 2020, doi: 10.3892/ijmm.2020.4555.
- 468

WITHDRAWN
see manuscript DOI for details

Table 1: Brief summary of the studies featured in the meta-analysis (N=33)

Authors	Country	Study Design	Number of eligible patients	Coronary artery disease	Key findings
Xie et al.(2020)	China	retrospective study	62	53.23%	The median age of all patients was 66.0 (53.3, 73.0) years old. Coronary artery disease (11.3%) and hypertension (38.7%) were the common coexisting CVDs in COVID-19 patients. High-sensitivity cardiac troponin I (hs-cTnI), creatinine, high-density lipoprotein-cholesterol, interleukin-6, C-reactive protein, prothrombin time, and D-dimer levels in the severe COVID-19 with CVD group were higher than in the non-severe COVID-19 with CVD group (P<0.05). For all patients, chest computed tomography (CT) showed ground-glass opacity (66.1%), local (21.0%), bilateral (77.4%), and interstitial abnormalities (4.8%). In COVID-19 patients with CVD, 27 (81.8%) were cured and discharged. 6 (18.2%) remained in hospital, including 2 (3.2%) patients requiring intubation and mechanical ventilation. The hs-cTnI levels in the remaining hospitalized patients were higher than in the discharged patients (P=0.047).
Aladağ et al.(2020)	Turkey	cross-sectional study	50	44.00%	There were no significant difference between survivors and non-survivors regarding age, gender, and pre-existing coronary artery disease, hypertension, diabetes, heart failure, coronary artery bypass grafting surgery, percutaneous coronary intervention and coronary stenting. Admission D-dimer and NT-proBNP levels of non-survivors were significantly higher than survivors. CRP, procalcitonin, creatine kinase (CK) and troponin I levels on 7th day of admission were significantly higher in non-survivors compared to survivors.
Barman et al.(2021)	Turkey	retrospective study	607	19.11%	A total of 607 hospitalized patients with COVID-19 were included in the study; the median age was 62.5 ± 14.3 years, and 334 (55%) were male. Cardiac injury was detected in 150 (24.7%) of patients included in the study. Mortality rate was higher in patients with cardiac injury (42% vs. 8%; P < 0.01). The frequency of patients who required ICU (72% vs. 19%), who developed acute kidney injury (14% vs. 1%) and acute respiratory distress syndrome (71%vs. 18%) were also higher in patients with cardiac injury. In multivariate analysis, age, coronary artery disease (CAD), elevated CRP levels, and presence of cardiac injury [odds ratio (OR) 10.58, 95% confidence interval (CI) 2.42–46.27; P < 0.001] were found to be
Bruce et al.(2020)	United kingdom	cross-sectional study	1222	22.34%	Overall in-hospital mortality was 29.3% (n = 358), varying from 12.2 to 43.9% across hospital sites. In-hospital mortality was 25.9% (n = 14) for the NSAID users and 29.5% (n = 344) among the non-users (p = 0.578). In-hospital mortality was higher in older age groups (39% in patients aged ≥80 years; 34.3% in those aged 65–79 years; 12.9% in patients aged <65 years) and for patients with comorbidities including diabetes (32.4% in patients with diabetes vs. 28.1% in those without),

					hypertension (32.6% vs. 25.7%), coronary artery disease (39.2% vs. 26.3%) and reduced renal function (eGFR < 60) on admission (38.7% vs. 23.1%). A complete breakdown of demographics and clinical characteristics by in-hospital mortality is
Cen et al.(2020)	China	cohort study	1007	6.45%	Multivariate Cox proportional hazards models identified that increased age (hazard ratio (HR) 2.56, 95% CI 1.97–3.33), male sex (HR 1.79, 95% CI 1.41–2.28), presence of hypertension (HR 1.44, 95% CI 1.11–1.88), diabetes (HR 1.82, 95% CI 1.35–2.44), chronic obstructive pulmonary disease (HR 2.01, 95% CI 1.38–2.93) and coronary artery disease (HR 1.83, 95% CI 1.26–2.66) were risk factors for disease progression. H
Gupta et al.(2020)	India	retrospective study	200	4.50%	predominance (116 patients out of 200, 58%). A majority of the patients (147, 73.5 %) were symptomatic, with fever being the most common symptom (109, 54.5%), followed by cough (91, 45.5%). The frequencies as recorded in decreasing order were systemic hypertension (46), diabetes mellitus (DM) (32), active tuber-culosis (TB) (11), and coronary artery disease (9). Notably, chronic kidney disease (4) and obstructive airway disease
Hewitt et al.(2020)	United kingdom and Italy	cohort study	1564	22.06%	s Between Feb 27, and April 28, 2020, we enrolled 1564 patients with COVID-19. The median age was 74 years (IQR 61–83); 903 (57.7%) were men and 661 (42.3%) were women; 425 (27.2%) had died at data cutoff (April 28, 2020). 772 (49.4%) were classed as frail (CFS 5–8) and 27 (1.7%) were classed as terminally ill (CFS 9). Compared with CFS 1–2, the adjusted hazard ratios for time from hospital admission to death were 1.55 (95% CI 1.00–2.41) for CFS 3–4, 1.83 (1.15–2.91) for CFS 5–6, and 2.39 (1.50–3.81) for CFS 7–9, and adjusted odds ratios for day-7 mortality were 1.22 (95% CI 0.63–2.38) for CFS 3–4, 1.62 (0.81–3.26) for CFS 5–6, and 3.12 (1.56–6.24) for CFS 7–9.
Iaccarino et al.(2020)	Italy	cohort study	1591	13.58%	At least 1 preexisting condition was observed in 73.4% of patients, with hypertension being the most represented (54.9%). One hundred eighty-eight deaths were recorded (11.8%; mean age, 79.6±0.9 years). In nonsurvivors, older age, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery diseases, and heart failure were more represented than in survivors.
Lagi et al.(2020)	Italy	cohort study	84	14.29%	n the pre- and post-intervention period, nine (29.0%) and seven (13.2%) patients were transferred to ICU. The overall rate of ICU transfers in our unit was 2.64 (95% confidence interval (CI): 1.62–4.31) per 100 patient days. The rate of ICU transfers in the post-intervention period compared with the pre-intervention period markedly decreased from 6.30 per 100 patient days, (95% CI: 3.00–

					13.22) to 1.82 patient days, (95% CI: 0.94–3.50). The unadjusted rate ratio (RR) for transfers for the post-intervention period was 0.28 (95% CI: 0.10–0.75; $p=0.0070$). After adjustment for sex, age, Horowitz index at baseline, diabetes mellitus, hypertension, COPD, coronary heart disease, the RR for the post-intervention period was 0.88 (95% CI: 0.82–0.95; $p=0.002$).
Lendorf et al.(2020)	Denmark	retrospective study	111	17.12%	A total of 115 patients were included, including four infants. The median age of adults was 68 years and 40% were female. At admission, 55 (50%) patients had a fever, 29 (26%) had a respiratory rate exceeding 24 breaths/minute, and 78 (70%) received supplemental oxygen. The prevalence of co-infection was 13%. Twenty patients (18%) (median age: 64 years; 15% female) were treated in the intensive care unit. Twelve (10.4%) received invasive mechanical ventilation and three (2.6%) renal replacement therapy. Nine patients (8%) developed pulmonary embolism. Sixteen patients (14%) died. Among patients requiring mechanical ventilation (n = 12), seven (6.1%) were discharged alive, four (3.4%) died and one (0.9%) was still hospitalised.
Li et al.(2020)	China	retrospective study	74	8.11%	Of the 74 patients enrolled in the study, 48 (64.9%) were severe cases and 26 (35.1%) were critical cases. Sixty (81.1%) patients were recovered and 14 (18.9%) died. Compared with recovery patients, patients in the death group were older, and had higher incidences of hypertension, coronary disease and dyspnea at admission. Laboratory tests for lactate dehydrogenase, creatine kinase, myoglobin, brain natriuretic peptide and D-dimer indicated higher levels in the death group. The PaO ₂ :FiO ₂ ratio and minimum SpO ₂ were lower in the death group, and a higher proportion of these patients received noninvasive mechanical ventilation, invasive mechanical ventilation and extracorporeal membrane oxygenation treatment.
Liao et al.(2020)	China	retrospective study	56	7.14%	A total of 56 patients progressed from mild or moderate to severe. We used least absolute shrinkage and selection operator regression model to select prognostic factors for this model. The case-severity rate was 3.6% in the shelter hospital. They were all symptomatic at admission. Fever, cough, and fatigue were the most common symptoms. Hypertension, diabetes and coronary heart diseases were common co-morbidities. Predictors contained in the prediction nomogram included fever, distribution of peak temperature (>38°C), myalgia or arthralgia and distribution of C-reactive protein (≥10 mg per L). The distribution of peak temperature (>38°C) on set, myalgia or arthralgia and C-reactive protein (≥10 mg per L) were the prognostic factors to identify the progression of COVID-19 patients with mild or moderate type. Early attention to these risk factors will help alleviate the progress of the COVID-19.
Turagam et al.(2020)	United states	retrospective cohort study	140	25.00%	The median (interquartile range) age was 61 years (48–74); 73% men; and ethnicity was White in 34%. Comorbidities included hypertension in 61%, coronary artery disease in 25%, ventricular arrhythmia history in 1.4%, and no significant comorbidities in 16%. Compared with discharged patients, those who died had elevated peak troponin I levels (0.27 versus 0.02 ng/mL) and more primary end point events (17% versus 4%, $P=0.01$)—a difference driven by tachyarrhythmias. Fatal

					tachyarrhythmias invariably occurred in the presence of severe metabolic imbalance, while atrioventricular block was largely an independent primary event.
Argenziano et al.(2020)	United states	retrospective study	1000	13.10%	Of the first 1000 patients, 150 presented to the emergency department, 614 were admitted to hospital (not intensive care units), and 236 were admitted or transferred to intensive care units. The most common presenting symptoms were cough (732/1000), fever (728/1000), and dyspnea (631/1000). Patients in hospital, particularly those treated in intensive care units, often had baseline comorbidities including hypertension, diabetes, and obesity. Patients admitted to intensive care units were older, predominantly male (158/236, 66.9%), and had long lengths of stay (median 23 days, interquartile range 12-32 days); 78.0% (184/236) developed acute kidney injury and 35.2% (83/236) needed dialysis. Only 4.4% (6/136) of patients who required mechanical ventilation were first intubated more than 14 days after symptom onset. Time to intubation from symptom onset had a bimodal distribution, with modes at three to four days, and at nine days. As of 30 April, 90 patients remained in hospital and 211 had died in hospital.
Chen et al.(2020)	China	retrospective cohort study	35	22.86%	Of the 1,590 cases included in this cohort, 50 deaths were reported by January 31, 2020. The median age of fatal cases was 69 years (range, 51-86 years); 30 of these subjects were male. The median duration from initial treatment to death was 11 days (interquartile range, 7-16.5 days). Thirty-five (70%) cases reported one or more co-existing illness: 28 (56.0%) with hypertension, 13 (26.0%) with diabetes, eight (16.0%) with coronary heart disease (CHD), six (12.0%) with cerebrovascular disease (CVD), six (12.0%) with COPD, and five (10.0%) with renal disease (Fig 1 A). The most common symptoms since disease onset were fever (87.5%), cough (77.1%), and dyspnea (74.0%). The incidence of dyspnea in fatal cases was higher than that in nonfatal cases (19.1%; P < .001).
Deng et al.(2020)	China	retrospective study	112	13.39%	Of the 112 patients, 58 (51.8%) had one or more co-existing conditions, and hypertension (36 [32.1%]), diabetes (19 [17.0%]) and coronary heart disease (CHD) (15 [13.4%]) were the most common co-existing conditions. The most common heart-related symptoms were fever (98 [87.5%]), cough (79 [70.5%]), chest pain/tightness (73 [65.2%]) and shortness of breath (63 [56.3%]).
Xingwei et al.(2020)	China	retrospective study	54	14.81%	The age of the 54 patients was 68.0(59.8, 74.3) years. Among all the patients, 24 (44.4%) patients were complicated with hypertension, 13 (24.1%) with diabetes, 8 (14.8%) with coronary heart disease, and 3 (5.6%) with previous cerebral infarction. During hospitalization, 24 (44.4%) of the patients were complicated with myocardial injury and 26 (48.1%) patients died in hospital. In-hospital mortality was significantly higher in patients with myocardial injury than in patients without myocardial injury (14 (60.9%) vs. 8 (25.8%), P=0.013). Moreover, the levels of C-reactive protein (153.6 (80.3, 240.7) ng/L vs. 49.8 (15.9, 101.9) ng/L) and N-terminal pro-B-type natriuretic peptide (852.0 (400.0, 2 315.3) ng/L vs. 197.0 (115.3, 631.0) ng/L) were significantly higher than

					patients without myocardial injury (all $P < 0.01$).
Lodigiani et al.(2020)	Italy	retrospective cohort study	388	13.92%	We included 388 patients (median age 66 years, 68% men, 16% requiring intensive care [ICU]). Thromboprophylaxis was used in 100% of ICU patients and 75% of those on the general ward. Thromboembolic events occurred in 28 (7.7% of closed cases; 95%CI 5.4%–11.0%), corresponding to a cumulative rate of 21% (27.6% ICU, 6.6% general ward). Half of the thromboembolic events were diagnosed within 24 h of hospital admission. Forty-four patients underwent VTE imaging tests and VTE was confirmed in 16 (36%). Computed tomography pulmonary angiography (CTPA) was performed in 30 patients, corresponding to 7.7% of total, and pulmonary embolism was confirmed in 10 (33% of CTPA). The rate of ischemic stroke and ACS/MI was 2.5% and 1.1%, respectively. Overt DIC was present in 8 (2.2%) patients.
Shi et al.(2020)	China	retrospective study	671	8.94%	A total of 2253 cases with confirmed COVID-19 were screened initially, from 1 January to 23 February 2020, in a tertiary teaching hospital with two integrated hospital districts and a cabin hospital. Figure 1 depicts the flowchart for participant selection. Briefly, after excluding cases with mild COVID-19 (1095), duplicated cases (156), and cases without available core medical information (331), 671 cases (death, 62; survivors, 609) with severe COVID-19 were enrolled in final analysis. In these patients, the median age was 63 years (IQR, 50–72 years), 48% of patients were male, and the median time from symptom and admission to end of follow-up was 23 days and 17 days, respectively. The most common main comorbidity was hypertension (29.7%), followed by diabetes (14.5%), coronary heart disease (8.9%), chronic renal disease (4.2%), chronic obstructive pulmonary disease (3.4%), cancer (3.4%), chronic heart failure (3.3%), cerebrovascular disease (3.3%), and atrial fibrillation (1.0%)
Tai et al.(2020)	China	retrospective cohort study	332	3.31%	Of the 332 patients with mild COVID-19, the median age was 51 years (IQR, 40-59 years), and 200 (61.2%) were female. Of the 48 (14.5%) patients with CV conditions, 23 (47.9%) progressed to severe disease status and required intensive care. Compared with patients without CV conditions, patients with CV conditions were older and more likely to have fatigue, chest tightness, and myalgia. The rate of requiring intensive care was significantly higher among patients with CV conditions than in patients without CV conditions (47.92% vs. 12.4%; $P < 0.001$). In subgroup analysis, the rate of requiring intensive care was also higher among patients with either hypertension or coronary heart disease (CHD) than in patients without hypertension or CHD. The multivariable regression model showed that CV condition served as an independent risk factor for intensive care (odds ratio (OR), 2.652 (95% CI, 1.019-6.899)) after

					adjustment for various cofounders. Conclusions. Patients with mild COVID-19 complicating CV conditions are susceptible to develop severe disease status and requirement for intensive care.
Rossi et al.(2020)	Italy	cohort study	1075	10.70%	Case fatality rate reached 20.7% in cases with more than 4 weeks follow up. After adjusting for age and comorbidities, men had a higher risk of hospitalization (HR 1.4 95% CI 1.2 to 1.6) and of death (HR 1.6, 95% CI 1.2 to 2.1). Patients over age 80 compared to age < 50 had HR 7.1 (95% CI 5.4 to 9.3) and HR 27.8 (95% CI 12.5 to 61.7) for hospitalization and death, respectively. Immigrants had a higher risk of hospitalization (HR 1.3, 95% CI 0.99 to 1.81) than Italians and a similar risk of death. Risk of hospitalization and of death were higher in patients with heart failure, arrhythmia, dementia, coronary heart disease, diabetes, and hypertension, while COPD increased the risk of hospitalization (HR 1.9, 95% CI 1.4 to 2.5) but not of death (HR 1.1, 95% CI 0.7 to 1.7).
Lax et al.(2020)	Austria	Prospective study	11	27.27%	: Patients' age ranged from 66 to 91 years (mean, 80.5 years, 8 men, 3 women). Ten of the 11 patients received prophylactic anticoagulant therapy; venous thromboembolism was not clinically suspected antemortem in any of the patients. Both lungs showed various stages of diffuse alveolar damage (DAD), including edema, hyaline membranes, and proliferation of pneumocytes and fibroblasts. Thrombosis of small and mid-sized pulmonary arteries was found in various degrees in all 11 patients
Inciari et al.(2020)	Italy	Case-control	99	16.16%	mong the cardiac patients, HF, atrial fibrillation (AF), coronary artery disease (CAD), and CKD were present in 40, 36, 30, and 28% of the patients, respectively. Cardiac patients were more likely to receive chronic treatment with an angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), or angiotensin receptor–neprilysin inhibitor (ARNI), anticoagulants, and statins. Fever on admission was present in 42% of patients. Chest X-ray showed pneumonia in all patients. No differences were found in any variable except for a lower blood pressure in cardiac patients.
Zhang et al.(2020)	China	cross-sectional study	140	5.00%	he SARS-CoV-2 clustered within 15 (10.7%) patients in this study, whose family members or friends were also infected with SARS-CoV-2. Three hospital workers were infected. Ninety (64.3%) patients had at least one underlying comorbidity, the most common of which were chronic diseases, such as hypertension (30%) and diabetes (12.1%).
Richardson et al.(2020)	United states	Case series	5700	10.44%	A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female) (Table 1). The median time to obtain polymerase chain reaction testing results was 15.4 hours (IQR, 7.8-24.3). The most common comorbidities were hypertension

					(3026, 56.6%), obesity (1737, 41.7%), and diabetes (1808, 33.8%). The median score on the Charlson Comorbidity Index was 4 points (IQR, 2-6), which corresponds to a 53% estimated 10-year survival and reflects a significant comorbidity burden for these patients. At triage, 1734 patients (30.7%) were febrile, 986 (17.3%) had a respiratory rate greater than 24 breaths/min, and 1584 (27.8%) received supplemental oxygen
Zhang et al.(2020)	China	cross-sectional study	143	11.89%	The mean age was 63±14 years; 74 (51.7%) patients were men. Comorbidities included hypertension, diabetes mellitus, coronary artery disease, malignancy, chronic liver disease, and chronic kidney disease. Only 1 (0.7%) patient had a history of VTE. Common symptoms at the onset of illness were fever, dry cough, fatigue, dyspnea, diarrhea, and headache.
Du et al.(2020)	China	retrospective study	85	11.76%	The median age of the patients was 65.8 years, and 72.9% were male. Common symptoms were fever (78 [91.8%]), shortness of breath (50 [58.8%]), fatigue (50 [58.8%]), and dyspnea (60 [70.6%]). Hypertension, diabetes, and coronary heart disease were the most common comorbidities.
Scoccia et al.(2021)	Italy	retrospective study	1625	68.92%	
Jamora et al., (2022)	Philippines	retrospective cohort study	10,881	3.90%	The incidence of stroke among patients with COVID-19 was 3.4% (n = 367). There were more deaths among patients with stroke and COVID-19 than those without stroke and COVID-19 (42.2% vs 14.7%, p < 0.01). In addition, more patients with stroke were admitted in the ICU (43.3% vs 15.0%, p < 0.01) regardless of cause. Smoking (OR: 1.5, 95% CI: 1.3 to 1.7, p < 0.0001), hypertension (OR:1.75, 95% CI:1.53 to 1.97, p < 0.0001), presence of heart failure (OR: 1.4, 95% CI: 1.07 to 1.86, p = 0.01), presence of any neurologic co-morbidities (OR: 1.4, 95% CI:1.11 to 1.46, p = 0.004), and history of stroke (OR:2.3, 95% CI:1.82 to 2.97, p < 0.0001) had direct significant correlation with stroke; while being a health care worker (OR: 0.5, 95% CI: 0.33 to 0.70, p < 0.0004) had an inverse significant association with stroke.
Bali et al. (2021)	India	retrospective cohort study	120	25.00%	A total of 22 patients in both the years presented as ST Elevation myocardial infarction. It was seen most commonly in 22% patients in the second wave. Anterior wall myocardial infarction was seen in 5% patients in 2020 and 12% patients in 2021. Unstable angina accounted for a majority of patients in the first wave (17%). Second most common cardiovascular complication seen was arrhythmia. The most common arrhythmia seen was atrial fibrillation seen in 6(10%) patients in 2020 and 7(12%) patients in 2021. Non-ST elevation myocardial infarction was seen in 6(10%) patients of the first wave and 2(3%) patients in the second wave, thus totaling to 8 patients over the two years. Left ventricular hypertrophy was seen in 13% patients last year and 3% patients this year. 22(37%) patients in the first wave and 2(35%) patients this year who had cardiovascular complications, died. 26(43%) patients in both the years were discharged after recovery.

Meloche et al, (2021)	USA	Prospective study	5019	13.51%	1149 patients (22.9%) had a history of CVD, including 13.5% with CAD, 10.2% with HF and 7.6% with AF. Compared to patients without CVD, those with were older
Slipczuk et al, (2021)	USA	retrospective cohort study	493	60.04%	Patients who died during the index admission had higher age (72, [64–80] vs 68, [57–76])
Prabhakaran et al. (2021)	Multinational	cohort study	5313	10.92%	Forty hospitals from 23 countries recruited 5,313 patients with COVID-19 (LIC = 7.1%, LMIC = 47.5%, UMIC = 19.6%, HIC = 25.7%). Mean age was 57.0 (\pm 16.1) years, male 59.4%, pre-existing conditions included: hypertension 47.3%, diabetes 32.0%, coronary heart disease 10.9%, and heart failure 5.5%. The most frequently reported cardiovascular discharge diagnoses were cardiac arrest (5.5%), acute heart failure (3.8%), and myocardial infarction (1.6%). The rate of in-hospital deaths was 12.9% (N = 683), and post-discharge 30 days deaths was 2.6% (N = 118) (overall death rate 15.1%). The most common causes of death were respiratory failure (39.3%) and sudden cardiac death (20.0%). The predictors of overall mortality included older age (\geq 60 years), male sex, pre-existing coronary heart disease, renal disease, diabetes, ICU admission, oxygen therapy, and higher respiratory rates ($p < 0.001$ for each). Compared to Caucasians, Asians, Blacks, and Hispanics had almost 2–4 times higher risk of death. Further, patients from LIC, LMIC, UMIC versus. HIC had 2–3 times increased risk of death.

Table 2: Subgroup analysis for pooled prevalence of coronary artery disease among COVID-19 patients – based on continent

Sub-group	No. of studies	Pooled estimate (95% CI)	tau ²	p value
Continent				<i>P</i> =.002
Asia	15	10.07% (6.55% - 15.19%)	0.76	
Europe	12	21.70% (14.80% - 30.65%)	0.62	
North America	5	21.02% (10.48% - 37.68%)	0.87	
Multinational	1	10.92% (10.11% - 11.78%)	-	




Figure 1. PRISMA flow chart for included studies in systematic review and meta-analysis of prevalence of coronary artery disease among COVID-19 patients




Figure 2. Pooled prevalence forest plot of coronary artery disease among COVID-19 patients.




Figure 3. Bubble plot based on the prevalence of coronary artery disease among COVID-19 patients




Figure 4. Doi plot and LFK index to assess publication bias and small-study effects for prevalence of coronary artery disease among COVID-19 patients.